Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

100.40 +1.63 (+1.65%)

Streaming Delayed Price Updated: 12:37 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

25 26 Next >

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales ↗

May 02, 2023

Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.

Via Investor's Business Daily

Why Incyte Shares Are Falling Today ↗

May 02, 2023

Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the

Via Benzinga

Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 02, 2023

From Incyte

Via Business Wire

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

May 01, 2023

From Incyte

Via Business Wire

Earnings Outlook For Incyte ↗

May 01, 2023

Via Benzinga

Ominous Death Cross Forms On Incyte's Chart ↗

April 13, 2023

Via Benzinga

What 13 Analyst Ratings Have To Say About Incyte ↗

March 28, 2023

Via Benzinga

Incyte Stock Dives On Surprise Rejection For Updated Jakafi ↗

March 24, 2023

The company had hoped to gain approval for an extended-release version of its biggest drug.

Via Investor's Business Daily

What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks ↗

April 21, 2023

Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain...

Via Benzinga

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

April 20, 2023

From Incyte

Via Business Wire

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conferences

April 18, 2023

From Incyte

Via Business Wire

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

April 16, 2023

From Incyte and MorphoSys U.S. Inc.

Via Business Wire

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗

April 14, 2023

One executive called this the most "damaging" decision in five decades.

Via Investor's Business Daily

Incyte to Report First Quarter Financial Results

April 11, 2023

From Incyte

Via Business Wire

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday ↗

April 10, 2023

Micron and Charles Schwab were among the top performers.

Via Investor's Business Daily

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target ↗

April 10, 2023

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

April 10, 2023

Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...

Via Benzinga

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

March 27, 2023

From Incyte

Via Business Wire

Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' ↗

March 24, 2023

Via Benzinga

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

March 23, 2023

From Incyte

Via Business Wire

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

March 22, 2023

From Incyte

Via Business Wire

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Why Shares of MacroGenics Climbed Thursday ↗

March 16, 2023

The cancer-focused biotech delivered a strong earnings report.

Via The Motley Fool

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

March 14, 2023

From Incyte Corporation

Via Business Wire

Which S&P 500 Stocks Look Most Attractive Now? ↗

March 08, 2023

Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.

Via Talk Markets

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.